Rise and shine. Another day awaits. And who knows what lies ahead? Meetings? Deadlines? Unexpected tidbits of information? We can relate. So grab a cup of stimulation - or perhaps, a bottle of water, since it will be rather sticky today in the greater Pharmalot metropolitan region - and dive in. As always, here are some items to ease the process. Have a great day everyone and stay in touch...
UK's NICE Won't Cover Bayer Liver Cancer Drug (Bloomberg News)
AMRI Cuts US Workforce 10% And Shifts Jobs To Asia (OutsourcingPharma)
FTC Commish Remains Bullish On Ending Pay-To-Delay Deals (PharmaTimes)
Dennis Quaid Sues Baxter Over Heparin Overdose (USA Today)
Merck Will Not Raise Its Dividend (Associated Press)
Sanofi-Aventis Will Reassign Global Media Ad Duties (MM&M)
Photo thx to darkpatator on flickr creative commons
3 Comments
At least Merck is still paying a dividend. Pharma stocks are still a good income-producing play. In fact, if you're high enough up in the company you'll be able to re-price your stock options lower in a declining market, so that when the stock finally goes back up (remember Newton's Law) you'll be able to makem out quite nicely when you cash out.
“We have changed our approach to appraising high-cost treatments which can potentially extend life for terminally ill patients,”
This statement was made by Andrew Dillon, CEO of NICE in the UK. This is why I believe that "health care reform" (i.e. Obamacare) has met such resistance in the United States because patients in this country would never tolerate such government intrusion into life-saving healthcare decisions. To put it more colloquially, we don't want government coming between our patients and out doctors.
Nexavar has some nasty side effects. My father chose not to use it because his quality of life would be horrible, not worth living that way for the extra 2.8 months!